Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Dado Medical
h-index: 10
Total citations: 1,234
Total papers: 76
Homepage:
http://www.dadomedical.cz/
Recent papers from Dado Medical
Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study
European Journal of Neurology · 2025
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine
JAMA Neurology · 2024
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives
JAMA Neurology · 2024
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Current Medical Research and Opinion · 2022
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
Advances in Therapy · 2021
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention
Cephalalgia · 2020
An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study
Journal of Pain Research · 2020
An Investigation into the Prevalence of Migraine and its Prophylactic Treatment Patterns in the Czech Republic
2020
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Cephalalgia · 2020
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Cephalalgia · 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Cephalalgia · 2019
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Cephalalgia · 2018